Cencora, Inc. 10-Q Summary: Quarter Ended March 31, 2026
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2026 (Fiscal Q2 2026). Cencora, Inc. operates as a pharmaceutical services company with two primary reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions. The company recently reorganized its reporting structure to align with growth priorities, moving certain businesses (including MWI Animal Health and U.S. Consulting Services) into an "Other" category while exploring strategic alternatives for them. A significant corporate development during the period was the acquisition of the majority of OneOncology, a physician-led oncology platform.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2026 | Six Months Ended Mar 31, 2026 |
|---|---|---|
| Revenue | $78.36 billion | $164.29 billion |
| Gross Profit | $3.59 billion | $6.66 billion |
| Operating Income | $1.14 billion | $1.90 billion |
| Net Income (Attributable to Cencora) | $1.64 billion | $2.20 billion |
| Diluted EPS | $8.40 | $11.27 |
| Operating Cash Flow | (Not provided for quarter) | ($0.97 billion) used |
| Total Debt | $12.39 billion | $12.39 billion |
| Cash and Equivalents | $2.18 billion | $2.18 billion |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 3.8% year-over-year (YoY) for the quarter and 4.7% for the six-month period. Growth was driven by volume increases in specialty products (including GLP-1s) and the impact of recent acquisitions.
- Profitability Surge: Net income attributable to Cencora more than doubled YoY for the quarter ($1.64B vs. $0.72B) and increased 82% for the six-month period ($2.20B vs. $1.21B). This was significantly boosted by a $1.09 billion non-cash gain on the remeasurement of the OneOncology equity investment.
- Acquisition Impact: The February 2026 acquisition of OneOncology ($7.39B total consideration) and the January 2025 acquisition of Retina Consultants of America (RCA) contributed to higher operating expenses and revenue.
- Asset Impairment: The company recorded a $249.5 million impairment of assets, including goodwill, related to its U.S. Consulting Services business, which is classified as held for sale.
- Working Capital: Operating cash flow turned negative ($0.97B used) for the six-month period, primarily due to a $2.2 billion decrease in accounts payable (timing of supplier payments) and increases in receivables and inventory.
Guidance, Outlook, and Risks
- Capital Allocation: The company increased its quarterly dividend by 9% to $0.60 per share. It maintains a $2.0 billion share repurchase authorization with $882.2 million remaining available, though no shares were repurchased in the six months ended March 31, 2026.
- Debt Financing: To fund the OneOncology acquisition, Cencora issued $3.0 billion in senior notes and borrowed $1.5 billion in term loans in February 2026. Total debt increased from $7.66 billion to $12.39 billion.
- Litigation Contingencies: The company maintains a $4.3 billion accrued liability for opioid-related litigation and settlements, payable over 13 years. Significant legal proceedings remain, including appeals in the West Virginia and Maryland opioid cases and ongoing DOJ investigations regarding controlled substance reporting.
- Strategic Divestitures: MWI Animal Health and U.S. Consulting Services are held for sale. The U.S. Consulting Services business was divested on April 30, 2026.
- Risk Factors: Key risks include macroeconomic volatility, geopolitical instability (Ukraine, Middle East), changes in U.S. healthcare policy (including the "One Big Beautiful Bill Act"), and the potential for unfavorable outcomes in ongoing opioid litigation.
Investor Verification Checklist
- OneOncology Integration: Verify the timeline for full consolidation of OneOncology practices and the realization of projected synergies.
- Opioid Liability Accuracy: Monitor the status of the West Virginia and Maryland appeals, as unfavorable rulings could materially increase the $4.3 billion accrued liability.
- Divestiture Execution: Confirm the final sale price and terms for the MWI Animal Health business, currently held for sale.
- Working Capital Trends: Assess whether the negative operating cash flow is a seasonal anomaly or a structural shift in payment terms with suppliers and customers.
- Debt Servicing: Review the impact of the increased debt load ($12.4B) on future interest expense and leverage ratios, particularly given the variable-rate portion of the new term loans.